Crohn's News Blog

Weblog – Informação sobre DII

Posts Tagged ‘chronic inflammatory

GSK moves Crohn’s disease drug into phase III

leave a comment »

Crohn’s disease

GlaxoSmithKline and its partner ChemoCentryx have started late-stage trials of GSK’786 for Crohn’s disease.

The initial study is a randomised, double-blind, placebo-controlled study that will involve approximately 600 patients to evaluate 500mg of ‘786 once-daily or twice-daily compared to placebo in patients with moderately-to-severely active Crohn’s disease.

The primary and key secondary endpoints are the proportion of subjects achieving a treatment-induced clinical response based on the Crohn’s Disease Activity Index (CDAI) and the proportion of subjects achieving clinical remission.
Leia o resto deste artigo »

Anúncios

Written by CarlAn

18/01/2011 at 18:46

%d bloggers like this: